Teva Pharmaceutical Industries (TEVA) Net Income - Minority (2018 - 2026)

Teva Pharmaceutical Industries has disclosed Net Income - Minority across 9 years of filings, most recently posting -$4.0 million for Q1 2026.

• Quarterly Net Income - Minority rose 42.86% year-over-year to -$4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.0 million (up 42.86% YoY) and the FY2025 annual result came in at -$4.0 million, up 42.86% from the prior year.
• Net Income - Minority steadied at -$4.0 million in Q1 2026, from -$4.0 million in the prior quarter.
• Over five years, Net Income - Minority peaked at -$4.0 million in Q3 2025 and troughed at -$916.0 million in Q1 2022.
• A 5-year average of -$393.1 million and a median of -$319.0 million in 2024 frame the typical range for Net Income - Minority.
• Annual changes were most pronounced in 2022 — Net Income - Minority gained 6.05% — and 2024, when it soared 98.87%.
• Tracing TEVA's Net Income - Minority over 5 years: stood at -$794.0 million in 2022, then increased by 21.91% to -$620.0 million in 2023, then surged by 98.87% to -$7.0 million in 2024, then soared by 42.86% to -$4.0 million in 2025, then changed by 0.0% to -$4.0 million in 2026.
• Business Quant data shows TEVA's Net Income - Minority at -$4.0 million in Q1 2026, -$4.0 million in Q4 2025, and -$4.0 million in Q3 2025.